ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.920
-0.070 (-3.52%)
May 5, 2025, 10:32 AM EDT - Market open
ProQR Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 18.91 | 6.51 | 3.59 | 1.34 | - | Upgrade
|
Other Revenue | 0.64 | 0.08 | 0.77 | 1.04 | 1.03 | Upgrade
|
Revenue | 19.55 | 6.59 | 4.36 | 2.38 | 1.03 | Upgrade
|
Revenue Growth (YoY) | 196.41% | 51.27% | 83.30% | 131.10% | -46.77% | Upgrade
|
Gross Profit | 19.55 | 6.59 | 4.36 | 2.38 | 1.03 | Upgrade
|
Selling, General & Admin | 13.66 | 16.24 | 18.65 | 17.37 | 13.69 | Upgrade
|
Research & Development | 36.36 | 25.15 | 50.87 | 42.22 | 38.14 | Upgrade
|
Operating Expenses | 50.02 | 41.38 | 69.52 | 59.59 | 51.82 | Upgrade
|
Operating Income | -30.47 | -34.79 | -65.16 | -57.21 | -50.79 | Upgrade
|
Interest Expense | -1.08 | -1.2 | -5.13 | -3.41 | -2.04 | Upgrade
|
Interest & Investment Income | 3.25 | 2.59 | 0.11 | 0.01 | 0.31 | Upgrade
|
Earnings From Equity Investments | - | - | -0.01 | -0.22 | -0.32 | Upgrade
|
Currency Exchange Gain (Loss) | -0.01 | -0.26 | 4.76 | 1.51 | -1.99 | Upgrade
|
Other Non Operating Income (Expenses) | 0.35 | 0.95 | 2.71 | -1.88 | -0.08 | Upgrade
|
EBT Excluding Unusual Items | -27.96 | -32.7 | -62.72 | -61.2 | -54.91 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | 0.51 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | 3.02 | - | - | - | Upgrade
|
Other Unusual Items | - | 1.87 | -1.39 | - | 8.42 | Upgrade
|
Pretax Income | -27.96 | -27.81 | -64.11 | -60.68 | -46.49 | Upgrade
|
Income Tax Expense | -0.2 | -0.08 | 0.1 | 0.12 | 0.12 | Upgrade
|
Earnings From Continuing Operations | -27.76 | -27.74 | -64.2 | -60.8 | -46.61 | Upgrade
|
Minority Interest in Earnings | - | -0.38 | -0.22 | 0.06 | 0.05 | Upgrade
|
Net Income | -27.76 | -28.12 | -64.42 | -60.74 | -46.57 | Upgrade
|
Net Income to Common | -27.76 | -28.12 | -64.42 | -60.74 | -46.57 | Upgrade
|
Shares Outstanding (Basic) | 86 | 81 | 72 | 64 | 50 | Upgrade
|
Shares Outstanding (Diluted) | 86 | 81 | 72 | 64 | 50 | Upgrade
|
Shares Change (YoY) | 6.26% | 13.08% | 11.62% | 28.21% | 21.99% | Upgrade
|
EPS (Basic) | -0.32 | -0.35 | -0.90 | -0.95 | -0.93 | Upgrade
|
EPS (Diluted) | -0.32 | -0.35 | -0.90 | -0.95 | -0.93 | Upgrade
|
Free Cash Flow | -37.81 | 20.18 | -69.22 | -26.5 | -47.98 | Upgrade
|
Free Cash Flow Per Share | -0.44 | 0.25 | -0.97 | -0.41 | -0.96 | Upgrade
|
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
Operating Margin | -155.91% | -527.60% | -1494.82% | -2405.80% | -4935.96% | Upgrade
|
Profit Margin | -142.05% | -426.43% | -1477.95% | -2554.25% | -4525.27% | Upgrade
|
Free Cash Flow Margin | -193.46% | 305.99% | -1587.89% | -1114.21% | -4663.17% | Upgrade
|
EBITDA | -29.58 | -34.11 | -64.38 | -56.55 | -48.44 | Upgrade
|
EBITDA Margin | -151.33% | - | - | - | - | Upgrade
|
D&A For EBITDA | 0.89 | 0.68 | 0.78 | 0.66 | 2.36 | Upgrade
|
EBIT | -30.47 | -34.79 | -65.16 | -57.21 | -50.79 | Upgrade
|
EBIT Margin | -155.91% | - | - | - | - | Upgrade
|
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.